FDA Rejects Regeneron's Eylea HD
The US Food and Drug Administration (FDA) has rejected a prefilled syringe version of Regeneron's ophthalmology blockbuster Eylea HD (aflibercept) due to manufacturing shortcomings.
Regeneron announced the setback in its Q3 earnings, stating that the FDA issued a complete response (CR) letter for Eylea HD's pre-filled syringe supplemental biologics licence application (sBLA).
The sole reason for the rejection was unresolved issues at a facility of its manufacturing partner, Novo Nordisk.
- The FDA uncovered problems during an inspection of Novo Nordisk's filling plant in Bloomington, Indiana, reported by Regeneron in August 2025.
- Regeneron plans to re-apply to the FDA with a new pre-filled syringe manufacturing filler in January 2026.
Author's summary: FDA rejects Eylea HD due to manufacturing issues.
More News
- Route 24, I-78 delays ease after early morning jackknifed tractor-trailer crash
- Will ARC Raiders Survive? A Deep Dive Into Its Future | Invision Game Community
- Hong Kong Tennis Open: last China players exit as top seed Bencic progresses
- Thursday's FTB: At least the Jays won
- AFN Releases Progress Report on Canada’s Implementation of the UN Declaration on the Rights of Indigenous Peoples Act – “Accelerated Action is Needed Now” - Assembly of First Nations
- How excess rains and poor wastewater management send microplastics into city lakes
- Austin Reaves cracks viral joke after buzzer-beater lifts Lakers to win
- KJ set to rejoin Umno ahead of Sabah polls
- Passenger traffic at Georgian airports reaches record 6.5 million in 2025
- Dutch election: D66 and PVV neck and neck with smallest difference ever